Larvol Delta - PrisMN-Phase-2-Study-to-Evaluate-the-Safety-and-Efficacy-of-Budoprutug-a-LowFucosylated-AntiCD19-mAb-in-Primary-Membranous-Nephropathy

budoprutug (TNT119) - Climb Bio

https://pagv3.virtual-meeting.org/era/era26/en-GB/pag/presentation/507539?guestPreview=1

Edgar Charles

Apr 13, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next